key: cord-0744739-ug9y7wzb
authors: Schönborn, Linda; Greinacher, Andreas
title: Longitudinal Aspects of Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)
date: 2022-03-07
journal: Semin Hematol
DOI: 10.1053/j.seminhematol.2022.03.001
sha: 568e436511fcd64414abda8b5297f465b76aea8d
doc_id: 744739
cord_uid: ug9y7wzb

In hundreds of patients worldwide, vaccination against COVID-19 with adenovirus vector vaccines (ChAdOx1 nCoV-19; Ad26.COV2.S) triggered platelet-activating anti-platelet factor 4 (PF4) antibodies inducing vaccine-induced immune thrombotic thrombocytopenia (VITT). In most VITT patients, platelet-activating anti-PF4-antibodies are transient and the disorder is discrete and non-recurring. However, in some patients platelet-activating antibodies persist, associated with recurrent thrombocytopenia and sometimes with relapse of thrombosis despite therapeutic-dose anticoagulation. Anti-PF4 IgG antibodies measured by enzyme-immunoassay (EIA) are usually detectable for longer than platelet-activating antibodies in functional assays, but duration of detectability is highly assay-dependent. As more than one vaccination dose against COVID-19 is required to achieve sufficient protection, at least 69 VITT patients have undergone subsequent vaccination with an mRNA vaccine, with no relevant subsequent increase in anti-PF4 antibody titers, thrombocytopenia, or thrombotic complications. Also, re-exposure to adenoviral vector-based vaccines in five VITT patients was not associated with adverse reactions. Although data are limited, vaccination against influenza also appears to be safe. SARS-CoV-2 infection reported in one patient with preceding VITT did not influence anti-PF4 antibody levels. We discuss how these temporal characteristics of VITT provide insights into pathogenesis.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes the coronavirus disease 2019 (COVID- 19) pandemic. Vaccination is key to controlling the pandemic. One of the most widely used vaccines against COVID-19 is the recombinant chimpanzee adenoviral (ChAdOx1-S) vector vaccine, ChAdOx1 nCoV-19 COVID-19 vaccine (Vaxzevria; Oxford/AstraZeneca). (1, 2) Adenovirus vector-based vaccines can rarely induce severe adverse effects. After vaccination with ChAdOx1 nCoV-19 (3) (4) (5) or the recombinant adenovirus type 26 vector COVID-19 Vaccine (Johnson & Johnson/Janssen),(6, 7) patients were described presenting with thrombosis at unusual sites, associated with moderate to severe thrombocytopenia. (8) (9) (10) This post-vaccination adverse event is now called vaccine-induced immune thrombotic thrombocytopenia (VITT; synonym, thrombosis with thrombocytopenia syndrome, TTS). VITT occurs in the majority of individuals after the first vaccination shot. Despite its low incidence, hundreds of cases have been described worldwide because of the very high number of people vaccinated. (5, 11, 12) Platelet-activating anti-platelet factor 4 (PF4) IgG antibodies have been identified as the cause of VITT. (8) (9) (10) (13) (14) (15) The presence of these anti-PF4 antibodies in sera of VITT patients can be confirmed by anti-PF4/polyanion enzyme-immunoassays (EIAs) and by PF4-enhanced platelet activation assays using washed platelets. (8) There are many similarities between VITT (5, (8) (9) (10) and autoimmune heparin-induced thrombocytopenia (aHIT) (16) (17) (18) (19) (20) . Particularly the variant of aHIT known as "spontaneous HIT syndrome" shows strong similarities with VITT regarding the clinical presentation and the in vitro characteristics of the anti-PF4 antibodies. Observational studies of VITT patients indicate that the immune response after vaccination occurs in the same 5-20 day time window (5, (8) (9) (10) as seen in HIT. (18) (19) (20) In contrast to classic HIT, however, in functional in vitro tests, platelet activation in VITT patients occurs in the presence of PF4 rather than low heparin concentrations. (8, 14, 21) Furthermore, the binding sites on PF4 differ between anti-PF4 antibodies in HIT and in VITT. (15) An unusual characteristic of the immune response in HIT (Warkentin et al. 2001(19) ) is the rapid decline of platelet-activating antibodies, often within weeks (median time to antibody non-detectability, ~7 weeks). In the majority of individuals antibodies are no longer detectable after three months. Antibodies reacting in the anti-PF4/heparin EIA are often detectable for a few more weeks (median time to non-detectability, ~15 weeks). (19) However, in aHIT pathogenic antibodies can persist considerably longer, occasionally even for years. (16, 17) The first follow-up analysis of VITT patients showed that platelet-activating antibodies are also transient in VITT. (22, 23) In the context of the pandemic this is of high interest, especially with regard to whether further vaccination against SARS-CoV-2 is possible without inducing a relapse of VITT. To achieve sufficient protection against COVID-19, individuals require at least two vaccination shots (24) (25) (26) , and additional booster vaccination shots were recently recommended.(27) Since VITT is a novel disorder first described only 9 months ago, few data exist on long-term follow-up including tolerance of further vaccinations. There is a high level of uncertainty regarding crucial issues such as duration of anticoagulation, or the safety of further vaccinations against COVID-19 after an episode of VITT.

In addition, it is likely that not all individuals who develop platelet-activating anti-PF4 antibodies post-vaccination experience a clinical breakthrough of VITT, similar to the wellknown situation in HIT, where prospective trials showed the presence of platelet activating anti-PF4/heparin antibodies in asymptomatic patients. (28) It has been shown in HIT that these asymptomatic patients are at risk for rapid-onset HIT upon re-exposure with heparin, as long as the platelet-activating antibodies are present. (29) Thus, in an analogous fashion, application of a second vaccine shot might be dangerous if platelet activating anti-PF4 antibodies are still present. As long as the constituent of the vaccine is not identified, which is interacting with PF4, it remains unclear, whether the amount given with a 500 µL vaccine shot is sufficient to facilitate platelet activation by the anti-PF4

antibodies.

This review summarizes observations on the dynamics of the VITT-inducing antibody response, the clinical course of VITT patients, and tolerance of further vaccinations against SARS-CoV-2.

Few data exist on the long-term course of anti-PF4 antibodies after an episode of VITT.

In Germany, we are monitoring a cohort of 65 VITT patients with a current follow-up period up to 9 months (Figure 1 ). The first follow-up data were recently reported in Schönborn et al. 2021(22) . In all patients, VITT was initially confirmed in the Greifswald laboratory with a positive in-house anti-PF4/heparin EIA(30) and a positive PF4enhanced washed platelet activation assay (8) . Subsequently, serum samples were periodically obtained for anti-PF4 antibody testing over a follow-up period of up to 39 weeks (>350 follow-up samples analyzed).

Over the follow-up period, the PF4-dependent platelet activation assay became negative In conclusion, anti-PF4 IgG antibody detectability by EIA persists for longer than antibody detectability by platelet activation assay. This pattern is similar to the dynamics of antibody seroreversion observed in HIT. (19) However, VITT antibodies appear to persist for longer than typically observed in HIT. One reason could be that VITT antibodies resemble more the profile of antibodies observed in aHIT, i.e., they do not need a cofactor (heparin) to bind to PF4 and are initially present in very high titers.

A few patients in our follow-up cohort show persistently high ODs in the anti-PF4/heparin EIA over the entire follow-up period. (23) Consistently high titers of anti-PF4 antibodies in VITT patients are also described by other groups. (32) This raises the issue of whether VITT can evolve into a chronic autoimmune disorder. However, the persistence of hightiter anti-PF4 antibodies may also reflect a misleading EIA "ceiling" effect. EIA ODs have a limited dynamic range, and once a certain antibody titer is reached, maximal ODs are measured, i.e., even a fivefold higher antibody titer would yield the same OD result. We therefore titrated the sera of these patients to measure them within the dynamic range of the assay. This showed again a substantial decline in antibody levels over time. IgG has a half-life of 21 days.(33) Persistence of antibodies beyond 9 months therefore makes it likely that the antibody-producing B-cells persist, but probably they produce less antibodies over time.

The variability in duration of the anti-PF4 antibodies between patients is likely determined by a composite of antibodies produced at the time of acute VITT and persistence of anti-PF4 antibody-producing B-cells. In case of extremely high antibody titers produced during the acute phase by short-lasting B cells, therapeutic plasma exchange (TPE) or immunoadsorption would be a rational treatment, and appears effective in some patients. (34, 35) On the other hand, immunosuppressive treatment might be needed in case of persisting anti-PF4 antibody-producing B cells. Differentiation between these two entities is not only relevant for treatment considerations but also for risk assessment. Patients with persisting antibody-producing B cells are likely at much higher risk to relapse compared to patients in whom these B cells produce anti-PF4 antibodies transiently.

In all VITT patients of our cohort, onset of clinical symptoms occurred in the typical time window between days 5 and 20 after vaccination, with very high anti-PF4/heparin IgG EIA ODs. High-titer anti-PF4 antibodies occurring as early as five days after vaccination cannot be explained by a primary immune response. As in HIT (18) On the other hand, after a strong secondary immune response, antibodies typically persist for months and years, especially if induced as a secondary response to vaccination. This is obviously not the case in the majority of patients with VITT. The temporal features of anti-PF4 IgG antibody decline after development of VITT is similar to the antibody dynamics in HIT. (19) However, the time to seroreversion seems to take somewhat longer than in HIT, likely because antibody levels in VITT patients are unusually high during acute VITT. (8, 9) The rapid decline of platelet-activating antibody levels indicates that the immune response in VITT, similar to that observed in HIT, does not follow the typical "classic" antibody response pattern. In a mouse model of HIT, the anti-PF4 immune response has been attributed to marginal zone B cells, (40) 

In HIT most patients show an increase in platelet counts within one week. (42) This is also the case for most VITT patients (43) (44) (45) (46) (47) , although no comprehensive analysis of platelet recovery has yet been performed in a large cohort. One must differentiate between those VITT patients who show refractory thrombocytopenia or a relapse of thrombocytopenia within or immediately after the acute episode(48, 49) (persisting VITT), and those who show decreasing platelet counts weeks or months after full recovery of the acute episode(50) (recurrent VITT). For each scenario a representative patient example is described below. In analogy to HIT (42) , persistent VITT could be defined as persistent thrombocytopenia for more than one month. In the German follow-up cohort, we observed 2 patients with ongoing anticoagulation who presented with recurrent thrombocytopenia that required treatment long after the initial episode of VITT.(23) One patient suffered from rethrombosis despite ongoing anticoagulation. In this patient, platelet-activating antibodies were still detectable until the last available blood sample, which was taken 29 weeks after initial onset of VITT. EIA OD levels were consistently high but showed decreasing ODs when we diluted the sera as described above. Whether this is a case of persisting VITT (in analogy to aHIT(16)) or just a result of very high antibody titres, requires a longer follow-up observation.

Another patient originally described by Günther et al. (50) presented with severe headache, thrombocytopenia (platelet count 37x10 9 /L) and elevated D-Dimers (>30mg/L) 12 days after vaccination with ChAdOx1 nCoV-19. CVST was confirmed by cranial imaging, followed by intracranial hemorrhage within 24h after admission. Due to recurrent thrombocytopenia, the patient received four courses of IVIG on two consecutive days until day 30 . Under treatment with prednisolone the platelet count remained >150x10 9 /L between days 40-90. However, after day 90, a new rapid decrease in platelet count of >50% was observed despite ongoing anticoagulation. The patient died after >20 weeks due to neurological sequelae caused by the initial VITT episode.

It is currently unclear why some patients develop a relapse of VITT despite ongoing anticoagulation, while other patients do not.

In patients with highly suspected or confirmed VITT, anticoagulation is one of the most important pillars of acute treatment. The NICE guidelines(56) recommend continuing anticoagulation until anti-PF4 antibodies are no longer detectable by EIA. Especially where platelet activation assays are not available, this is a useful approach. However, Platton et al. (57) showed that detection of anti-PF4-antibodies over a follow-up period is assay-dependent. For instance, the Zymutest EIA detected anti-PF4-antibodies in one patient at the initial VITT episode, but not 14 weeks later; however, platelet-activating antibodies were still detectable by functional assay. As the authors recommend, monitoring of platelet counts and D-Dimer likely reveal patients with a remaining prothrombotic state.

In a few patients, VITT occurs with no thrombosis. (43, 58, 59) We enrolled 8 patients who fulfill the criteria of so-called "pre-VITT" in our longitudinal study. Their plateletactivating antibodies persisted for a median 10 weeks (range 4-24 weeks) after the acute episode of VITT. Two of them were already anticoagulated when VITT manifested due to atrial fibrillation.

Another pre-VITT patient (originally included in Salih et al. (43) ) is a 54-year-old female who presented with severe headache, thrombocytopenia of 66x10 9 /L and D-Dimers of 4.3 mg/L eight days after vaccination with ChAdOx1 nCoV-19. Cranial imaging did not reveal any thrombosis. The patient was treated with 5mg apixaban but after one dose she developed a drug exanthema and anticoagulation was stopped. Platelet count recovered slowly without further treatment (see Figure 3 ). Platelet-activating PF4dependent antibodies persisted for 24 weeks after the acute episode of VITT. However, her platelet counts remained stable, while D-Dimer was not measured after the acute episode. These anecdotal observations indicate that also in pre-VITT patients plateletactivating antibodies may persist for many weeks or even months. However, it is recommended for patients with pre-VITT that anticoagulation be given at least until platelet counts have normalized. As in classic HIT, reduced platelet counts indicate intravascular platelet activation and a prothrombotic state, and anticoagulation likely prevents further thrombus formation. (43) In summary, serial platelet counts and D-Dimer levels are likely more important parameters to guide clinical management of VITT and pre-VITT patients than anti-PF4 antibody titers or the presence of platelet-activating PF4-dependent antibodies

Ad26.COV2.S(26) require at least two vaccination shots to achieve sufficient protection against COVID-19, including against new variants of the SARS-CoV-2 virus. In most patients, VITT occurred after the first vaccination shot, (5, 11) and thus immunization against SARS-CoV-2 is incomplete. In summary, further vaccination against SARS-CoV-2 with mRNA vaccines is safe in patients with VITT. Furthermore, this is strong in vivo evidence indicating that the mRNA vaccines do not contain the cofactor(s) required for anti-PF4 antibody-mediated prothrombotic activation of platelets.

It is known from HIT that a brief reexposure to heparin is well tolerated in most patients, Whether platelet-activating antibodies were still detectable at the time of second vaccination was not analyzed. Therefore, repeat vaccination with an adenovirus vector vaccine in VITT patients seems to be feasible but more data are required before a definite recommendation can be given.

Beyond VITT the temporal data of the anti-PF4 immune response have implications for planning vaccination campaigns. To speed up the vaccination campaign the recommended three months time interval between the two vaccination shots of ChAdOx1 nCoV-19 has been shortened in some countries. This will increase the risk of applying the vaccine to still asymptomatic individuals with circulating PF4-dependent platelet activating antibodies developed after the first vaccination shot. Whether this increases the risk of adverse events is currently unresolved. A potential signal can be obtained by including the time period between first and second vaccination into reports of adverse vaccination events.

It is known from HIT(18) that HIT requires a polyanionic cofactor (i.e, heparin) that complexes with PF4 to induce the immune response. To date, the analogous cofactor involved in the development of VITT has not been identified (but does not appear to be contaminating heparin-like glycosaminoglycans in the vaccine). (63) As long as it is unclear whether any constituent of the vaccine beside the adenovirus and/or its proteins are key for triggering the immune response of VITT, it is not possible to predict, which other vaccines may increase risk of VITT recurrence.

VITT was discovered rapidly because the total number of cases was high, and because a widely available screening test for anti-PF4 antibodies (EIA) was strongly positive.

Never before in medical history have so many people been simultaneously vaccinated with the same vaccines. This suggests that VITT may have occurred before with other vaccines, but not have been recognized. In this regard, a recently described case of VITT after vaccination against human papilloma virus (Gardasil) is especially interesting. 

In the spring of 2021, the first cases of VITT appeared. Few data exist on the long-term course of VITT. In the majority of patients with VITT the anti-PF4 immune response is transient with a rapid decline of platelet-activating PF4-dependent antibodies, which dis-appear within [16] [17] [18] [19] [20] weeks. This seroreversion profile shows similarities to the HIT immune response, although antibody detectability seems to last somewhat longer in VITT.

After the initial episode of VITT, most patients recover without further thrombotic complications. In most patients with persisting platelet-activating, PF4-dependent antibodies, therapeutic-dose anticoagulation seems to sufficiently control thrombin generation.

However, few patients 2/65 (3%) show recurrent episodes of thrombocytopenia and/or thrombosis despite therapeutic-dose anticoagulation. In them recurrence was associated with persistence of platelet-activating antibodies. Whether these patients may benefit from immunosuppressive treatment is currently unresolved. The optimal duration of anticoagulation of VITT patients with and without thrombosis is unclear. Platelet count course and D-Dimer levels are likely more relevant to identify patients with a persisting prothrombotic state than anti-PF4 antibody monitoring. Careful monitoring is especially relevant when therapeutic-dose anticoagulation initiated because of the thrombotic complication of VITT is stopped, to identify patients who may require longer anticoagulation.

A second vaccination shot with the mRNA vaccines Comirnaty (BioNTech/Pfizer) or

Moderna after an episode of VITT appears to be safe, independent of the persistence of platelet-activating anti-PF4 antibodies and preliminary observations indicate that even reexposure with an adenovector based vaccine is also safe and efforts should be made to obtain this information given the relevance of adenovirus vector-based vaccines for low and middle income countries and the need of future vaccinations in VITT patients.

Finally, influenza vaccination in VITT patients also seems to be safe although numbers are still very small. 

Report of the Independent Allocation of Vaccines Group on the allocation of COVAX Facility secured vaccines

COVID-19 vaccine tracker and landscape

Coronavirus vaccine -weekly summary of Yellow Card reporting

Clinical Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

US Case Reports of Cerebral Venous Sinus Thrombosis With Thrombocytopenia After Ad26.COV2.S Vaccination

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Pathologic Antibodies to Platelet Factor 4 after ChAdOx1 nCoV-19 Vaccination

Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination

Laboratory confirmed vaccine-induced immune thrombotic thrombocytopenia: Retrospective analysis of reported cases after vaccination with ChAdOx-1 nCoV-19 in Germany. The Lancet Regional Health -Europe

Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine -United States

Antibody-mediated procoagulant platelets in SARS-CoV-2-vaccination associated immune thrombotic thrombocytopenia

PF4 Immunoassays in Vaccine-Induced Thrombotic Thrombocytopenia

Antibody epitopes in vaccine-induced immune thrombotic thrombocytopenia

Autoimmune heparin-induced thrombocytopenia

Spontaneous HIT syndrome: Knee replacement, infection, and parallels with vaccine-induced immune thrombotic thrombocytopenia

Heparin-Induced Thrombocytopenia

Temporal aspects of heparin-induced thrombocytopenia

The temporal profile of the anti-PF4/heparin immune response

Insights in ChAdOx1 nCoV-19 vaccine-induced immune thrombotic thrombocytopenia

Decline in Pathogenic Antibodies over Time in VITT

Antibodies in Vaccine-induced Immune Thrombotic Thrombocytopenia are transient

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Comparative Effectiveness of Moderna

Fibronectin modulates formation of PF4/heparin complexes and is a potential factor for reducing risk of developing HIT

Prevalence and risk of preexisting heparin-induced thrombocytopenia antibodies in patients with acute VTE

Incidence and clinical significance of anti-PF4/heparin antibodies of the IgG, IgM, and IgA class in 755 consecutive patient samples referred for diagnostic testing for heparin-induced thrombocytopenia

Evaluation of laboratory assays for anti-platelet factor 4 antibodies after ChAdOx1 nCOV-19 vaccination

Anti-PF4 levels of patients with VITT do not reduce 4 months following AZD1222 vaccination

Metabolic properties of IgG subclasses in man

Rare case of COVID-19 vaccine-associated intracranial haemorrhage with venous sinus thrombosis

Therapeutic Plasma Exchange in Vaccine-Induced Immune Thrombotic Thrombocytopenia

Platelet factor 4 binds to bacteria, [corrected] inducing antibodies cross-reacting with the major antigen in heparin-induced thrombocytopenia

Insights into the evolution of a complex virus from the crystal structure of vaccinia virus D13

The Structure of ChAdOx1/AZD-1222 Reveals Interactions with CAR and PF4 with Implications for Vaccine-induced Immune Thrombotic Thrombocytopenia

Comparative analysis of ChAdOx1 nCoV-19 and Ad26.COV2.S SARS-CoV-2 vector vaccines. Nature Portfolio

B-cell tolerance regulates production of antibodies causing heparin-induced thrombocytopenia

Marginal zone B cells: virtues of innate-like antibody-producing lymphocytes

Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia

Vaccine-Induced Thrombocytopenia with Severe Headache

Vaccine-induced immune thrombotic thrombocytopenia following AstraZeneca (ChAdOx1 nCOV19) vaccine-A case report

Massive cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocytopenia

Long-term followup after successful treatment of vaccine-induced prothrombotic immune thrombocytopenia

Successful venous thromboprophylaxis in a patient with vaccine-induced immune thrombotic thrombocytopenia (VITT): a case report of the first reported case in Thailand

Vaccine-induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism

Clinical course, management, and platelet activity assessment of splanchnic VITT: A case report

Complicated Long Term Vaccine Induced Thrombotic Immune Thrombocytopenia-A Case Report. Vaccines (Basel)

Vaccine induced immune thrombocytopenia and thrombosis: summary of NICE guidance

Diagnosis and Management of Vaccine-Related Thrombosis following AstraZeneca COVID-19 Vaccination: Guidance Statement from the GTH

Vaccine-induced immune thrombotic thrombocytopenia (VITT): Update on diagnosis and management considering different resources

Platelet Activation by Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT) Patient Serum is Blocked by COX, P2Y<sub>12</sub> and Kinase Inhibitors. medRxiv. 2021:2021.04.24.21255655. 56. NICE. COVID-19 rapid guideline: vaccine-induced immune thrombocytopenia and thrombosis (VITT). : The National Institute for Health and Care Excellence (NICE)

Vaccine-induced immune thrombocytopenia and thrombosis: The decline in anti-platelet factor 4 antibodies is assay-dependent

Delayed headache after COVID-19 vaccination: a red flag for vaccine induced cerebral venous thrombosis

VITT following Ad26.COV2.S vaccination presenting without radiographically demonstrable thrombosis

Heterogeneity of vaccine-induced immune thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination and safety of second vaccination with BNT162b2

VITT and Second Doses of Covid-19 Vaccine

Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are reexposed to heparin

The COVID-19 vaccine ChAdOx1-S is not contaminated with sulfated glycosaminoglycans

Thrombosis and thrombocytopenia after HPV vaccination

Anti-platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein